MedTrace Logo

Migraine Treatment With Nerivio Migra Neurostimulation Device

NCT03076515 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-07-17

Study results available
· View outcomes & findings →

Summary

This is a prospective, randomized, double-blind, sham controlled multi-center trial. Ratio between treatment and control groups will be 1:1, stratified by center and use of preventive medications.

Conditions

  • Acute Migraine

Interventions

DEVICE

Nerivio Migra neurostimulation

transcutaneous electrical stimulation

DEVICE

Sham Nerivio Migra

electrical stimulation- shame mode

Sponsors & Collaborators

  • Theranica

    lead INDUSTRY

Principal Investigators

  • Brian M Grosberg, MD · Hartford Healthcare Headache Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-02
Primary Completion
2018-01-31
Completion
2018-04-01
FDA Device
Yes

Countries

  • United States
  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03076515 on ClinicalTrials.gov